Homepage Top Section2

This marks a significant step in the potential approval of the medication for use in the European Union. One application pertains to the treatment of adults with locally

The financing round was led jointly by Alaska Permanent Fund Corporation, Cure Ventures, and The Column Group, with additional contributions from Euclidean Capital and Saisei Ventures. Previously operating

This development is based on pre-clinical findings of the drug in treating pancreatic cancer, a condition with a notably low five-year survival rate and limited treatment options. SNB-101

The facility, which will be operational this month, is designed to meet the increasing demand for life science products in the region. Spanning 13,000m2, the centre is twice

The investment, led by MSD Global Health Innovation Fund and IQ Capital, with contributions from Hoxton Ventures, Creator Fund, Beast Ventures, and Maki.vc, will expedite the progress of

The recommendation for granting Type II variation approval supports the use of cilta-cel for adult patients with RRMM who have received a minimum of one therapy earlier, including

Artiva had previously secured FDA clearance for an investigational new drug application for AlloNK plus rituximab for LN. This marked the first IND clearance for an allogeneic, off-the-shelf

Concurrently, the European Medicines Agency (EMA) granted accelerated assessment for the marketing authorization application (MAA) of the same drug. On receipt of approval, vorasidenib would become the sixth

The financing round was spearheaded by Broadview Ventures, with additional support from current investor SCVC and new participant MEIF Proof of Concept & Early Stage Fund. Mercia Ventures